| Subgroup | No. of studies | Heterogeneity | OR/MD [95%CI] | |
---|---|---|---|---|---|
I2 % | p | ||||
12-month recurrence | RCT | 2 | 0 | 0.93 | 0.98 [0.62, 1.55] |
Prospective | 1 | NA | 0.26 | 0.54 [0.19, 1.58] | |
Retrospective | 6 | 0 | 0.06 | 0.59 [0.33, 1.03] | |
Epirubicin | 5 | 0 | 0.68 | 0.92 [0.61, 1.37] | |
Mitomycin | 2 | 23 | 0.04 | 0.31 [0.10, 0.93] | |
Pirarucin | 1 | NA | 0.65 | 0.79 [0.29, 2.18] | |
Epirubicin + BCG | 1 | NA | 0.26 | 0.77 [0.55, 1.07] | |
24-month recurrence | RCT | 2 | 0 | 0.19 | 0.70 [0.41, 1.19] |
Prospective | 2 | 19 | 0.02 | 0.43 [0.21, 0.89] | |
Retrospective | 10 | 0 | 0.006 | 0.64 [0.47, 0.88] | |
Epirubicin | 7 | 0 | 0.13 | 0.71 [0.45, 1.10] | |
Mitomycin | 4 | 0 | 0.01 | 0.61 [0.41, 0.90] | |
Pirarucin | 2 | 0 | 0.14 | 0.65 [0.36, 1.16] | |
BCG | 1 | NA | 0.03 | 0.24 [0.07, 0.84] | |
36-month recurrence | Â | 4 | 58 | 0.32 | 0.72 [0.37, 1.39] |
Same site recurrence | Â | 5 | 0 | 0.10 | 0.49 [0.21, 1.14] |
Recurrence | Low-risk | 5 | 0 | 0.96 | 1.01 [0.63, 1.63] |
Intermediate-risk | 4 | 0 | 0.26 | 0.76 [0.47, 1.23] | |
High-risk | 3 | 0 | 0.76 | 0.82 [0.24, 2.85] |